Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure

While inhaled polycyclic aromatic hydrocarbons have long been suspected to induce lung cancer in humans, their dosimetry has not been fully elucidated. A key question is whether the critical exposure occurs during absorption in the lungs, or if toxicants in the systemic circulation contribute signif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) 1998-03, Vol.19 (3), p.493-500
Hauptverfasser: GERDE, P, MUGGENBURG, B. A, SCOTT, G. G, LEWIS, J. L, PYON, K. H, DAHL, A. R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 500
container_issue 3
container_start_page 493
container_title Carcinogenesis (New York)
container_volume 19
creator GERDE, P
MUGGENBURG, B. A
SCOTT, G. G
LEWIS, J. L
PYON, K. H
DAHL, A. R
description While inhaled polycyclic aromatic hydrocarbons have long been suspected to induce lung cancer in humans, their dosimetry has not been fully elucidated. A key question is whether the critical exposure occurs during absorption in the lungs, or if toxicants in the systemic circulation contribute significantly to lung cancer risk. In particular, data are needed to determine how the physical properties of inhalants affect local dosimetry in the respiratory tract. Pyrene, a tobacco smoke component, was selected for study because it has physical properties between those of highly lipophilic benzo[a]pyrene and water-soluble nitrosamines. Aliquots of 5 ng of pyrene dissolved in a phospholipid/ saline suspension were instilled as a single-spray bolus in the posterior trachea of the dog just anterior to the carina. For 3 h after instillation, blood was repeatedly sampled from the azygous vein, which drains the mucosa around the point of instillation, and from both sides of the systemic circulation. At 3 h post-instillation, tissue samples were taken. Autoradiography was used to determine the depth distribution of pyrene in the tracheal mucosa. The concentration of pyrene-equivalent radioactivity in the azygous vein peaked 9 min after the instillation. At approximately 30 min after instillation, a rapid early clearance phase shifted into a distinctly slower second clearance phase. Rates of rapid clearance were, however, sufficiently slow to indicate diffusion-limited absorption of pyrene in the trachea. This finding was corroborated by high concentrations of pyrene in the epithelium as determined by autoradiography. High epithelial concentration of pyrene combined with a slow penetration into the circulating blood allowed substantial first-pass metabolic conversion of pyrene in the tracheal mucosa. A total of 13% of the instilled pyrene was retained in the tracheal mucosa 3.2 h after instillation; of this, 29% was parent compound, 52% was organic-extractable metabolites, 14% was water-soluble metabolites and 6% (approximately 1% of the instilled amount) was covalently bound to tracheal tissues. Results support the inference that lipophilic protoxicants, because of slow, diffusion-limited absorption, are more likely than water-soluble protoxicants to be bioactivated in the lining epithelium and, in turn, induce first-pass toxicity at the site of entry. In addition, limitations were identified in the use of systemically distributed biomarkers of PAHs, such as urinary hy
doi_str_mv 10.1093/carcin/19.3.493
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_435352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36612551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-757ba7de5d42d19c1b437264f8833a04d9e6b5fd98b343f978468aabf254bab63</originalsourceid><addsrcrecordid>eNpdkb2P1DAQxSMEOpaDmgrJQoguu_5M4hKd-JJWooHaGjsTzneJvdiJ7lLxr2PYaAsqj-f9_GasV1WvGd0zqsXBQXI-HJjei73U4km1Y7KhNWcdfVrtKJOiFkLI59WLnO8oZY1Q-qq60oor3qld9fsYHYxkwhlsHH2eiA9kXMJPAj49wJrL3SWEjJnMt0iW4DDN4MO8kjiQ05owIIFMgFgfJ0j3mP4JcVzd6kbvCKTSn0txu_apTEs2BoKPp5iXhC-rZwOMGV9t53X149PH7zdf6uO3z19vPhxrJ1U3161qLbQ9ql7ynmnHrBQtb-TQdUIAlb3Gxqqh150VUgy67WTTAdiBK2nBNuK6qs---QFPizWn5Muyq4ngzda6LxUaKZRQvPDvz_wpxV8L5tlMPjscRwgYl2xYIxlveVfAt_-Bd3FJofzFcKZF8WpUgQ5nyKWYc8LhMp9R8zdHc87RMG2EKTmWF28228VO2F_4Lbiiv9t0yCXAIUFwPl8wzlqtqRB_AHUnqbo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219335265</pqid></control><display><type>article</type><title>Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>GERDE, P ; MUGGENBURG, B. A ; SCOTT, G. G ; LEWIS, J. L ; PYON, K. H ; DAHL, A. R</creator><creatorcontrib>GERDE, P ; MUGGENBURG, B. A ; SCOTT, G. G ; LEWIS, J. L ; PYON, K. H ; DAHL, A. R</creatorcontrib><description>While inhaled polycyclic aromatic hydrocarbons have long been suspected to induce lung cancer in humans, their dosimetry has not been fully elucidated. A key question is whether the critical exposure occurs during absorption in the lungs, or if toxicants in the systemic circulation contribute significantly to lung cancer risk. In particular, data are needed to determine how the physical properties of inhalants affect local dosimetry in the respiratory tract. Pyrene, a tobacco smoke component, was selected for study because it has physical properties between those of highly lipophilic benzo[a]pyrene and water-soluble nitrosamines. Aliquots of 5 ng of pyrene dissolved in a phospholipid/ saline suspension were instilled as a single-spray bolus in the posterior trachea of the dog just anterior to the carina. For 3 h after instillation, blood was repeatedly sampled from the azygous vein, which drains the mucosa around the point of instillation, and from both sides of the systemic circulation. At 3 h post-instillation, tissue samples were taken. Autoradiography was used to determine the depth distribution of pyrene in the tracheal mucosa. The concentration of pyrene-equivalent radioactivity in the azygous vein peaked 9 min after the instillation. At approximately 30 min after instillation, a rapid early clearance phase shifted into a distinctly slower second clearance phase. Rates of rapid clearance were, however, sufficiently slow to indicate diffusion-limited absorption of pyrene in the trachea. This finding was corroborated by high concentrations of pyrene in the epithelium as determined by autoradiography. High epithelial concentration of pyrene combined with a slow penetration into the circulating blood allowed substantial first-pass metabolic conversion of pyrene in the tracheal mucosa. A total of 13% of the instilled pyrene was retained in the tracheal mucosa 3.2 h after instillation; of this, 29% was parent compound, 52% was organic-extractable metabolites, 14% was water-soluble metabolites and 6% (approximately 1% of the instilled amount) was covalently bound to tracheal tissues. Results support the inference that lipophilic protoxicants, because of slow, diffusion-limited absorption, are more likely than water-soluble protoxicants to be bioactivated in the lining epithelium and, in turn, induce first-pass toxicity at the site of entry. In addition, limitations were identified in the use of systemically distributed biomarkers of PAHs, such as urinary hydroxypyrene levels, as indicators of the biologically effective dose in airway target cells.</description><identifier>ISSN: 0143-3334</identifier><identifier>ISSN: 1460-2180</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/19.3.493</identifier><identifier>PMID: 9525285</identifier><identifier>CODEN: CRNGDP</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Biological and medical sciences ; Biomarkers ; Body Burden ; Carcinogenesis, carcinogens and anticarcinogens ; Chemical agents ; Chromatography, High Pressure Liquid ; Dogs ; Female ; Half-Life ; Male ; Medical sciences ; Polycyclic Compounds - metabolism ; Polycyclic Compounds - toxicity ; Pyrenes - administration &amp; dosage ; Pyrenes - pharmacokinetics ; Trachea - blood supply ; Trachea - metabolism ; Tumors</subject><ispartof>Carcinogenesis (New York), 1998-03, Vol.19 (3), p.493-500</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Mar 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-757ba7de5d42d19c1b437264f8833a04d9e6b5fd98b343f978468aabf254bab63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2179903$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9525285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:14763938$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>GERDE, P</creatorcontrib><creatorcontrib>MUGGENBURG, B. A</creatorcontrib><creatorcontrib>SCOTT, G. G</creatorcontrib><creatorcontrib>LEWIS, J. L</creatorcontrib><creatorcontrib>PYON, K. H</creatorcontrib><creatorcontrib>DAHL, A. R</creatorcontrib><title>Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>While inhaled polycyclic aromatic hydrocarbons have long been suspected to induce lung cancer in humans, their dosimetry has not been fully elucidated. A key question is whether the critical exposure occurs during absorption in the lungs, or if toxicants in the systemic circulation contribute significantly to lung cancer risk. In particular, data are needed to determine how the physical properties of inhalants affect local dosimetry in the respiratory tract. Pyrene, a tobacco smoke component, was selected for study because it has physical properties between those of highly lipophilic benzo[a]pyrene and water-soluble nitrosamines. Aliquots of 5 ng of pyrene dissolved in a phospholipid/ saline suspension were instilled as a single-spray bolus in the posterior trachea of the dog just anterior to the carina. For 3 h after instillation, blood was repeatedly sampled from the azygous vein, which drains the mucosa around the point of instillation, and from both sides of the systemic circulation. At 3 h post-instillation, tissue samples were taken. Autoradiography was used to determine the depth distribution of pyrene in the tracheal mucosa. The concentration of pyrene-equivalent radioactivity in the azygous vein peaked 9 min after the instillation. At approximately 30 min after instillation, a rapid early clearance phase shifted into a distinctly slower second clearance phase. Rates of rapid clearance were, however, sufficiently slow to indicate diffusion-limited absorption of pyrene in the trachea. This finding was corroborated by high concentrations of pyrene in the epithelium as determined by autoradiography. High epithelial concentration of pyrene combined with a slow penetration into the circulating blood allowed substantial first-pass metabolic conversion of pyrene in the tracheal mucosa. A total of 13% of the instilled pyrene was retained in the tracheal mucosa 3.2 h after instillation; of this, 29% was parent compound, 52% was organic-extractable metabolites, 14% was water-soluble metabolites and 6% (approximately 1% of the instilled amount) was covalently bound to tracheal tissues. Results support the inference that lipophilic protoxicants, because of slow, diffusion-limited absorption, are more likely than water-soluble protoxicants to be bioactivated in the lining epithelium and, in turn, induce first-pass toxicity at the site of entry. In addition, limitations were identified in the use of systemically distributed biomarkers of PAHs, such as urinary hydroxypyrene levels, as indicators of the biologically effective dose in airway target cells.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Body Burden</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>Chemical agents</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Dogs</subject><subject>Female</subject><subject>Half-Life</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Polycyclic Compounds - metabolism</subject><subject>Polycyclic Compounds - toxicity</subject><subject>Pyrenes - administration &amp; dosage</subject><subject>Pyrenes - pharmacokinetics</subject><subject>Trachea - blood supply</subject><subject>Trachea - metabolism</subject><subject>Tumors</subject><issn>0143-3334</issn><issn>1460-2180</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkb2P1DAQxSMEOpaDmgrJQoguu_5M4hKd-JJWooHaGjsTzneJvdiJ7lLxr2PYaAsqj-f9_GasV1WvGd0zqsXBQXI-HJjei73U4km1Y7KhNWcdfVrtKJOiFkLI59WLnO8oZY1Q-qq60oor3qld9fsYHYxkwhlsHH2eiA9kXMJPAj49wJrL3SWEjJnMt0iW4DDN4MO8kjiQ05owIIFMgFgfJ0j3mP4JcVzd6kbvCKTSn0txu_apTEs2BoKPp5iXhC-rZwOMGV9t53X149PH7zdf6uO3z19vPhxrJ1U3161qLbQ9ql7ynmnHrBQtb-TQdUIAlb3Gxqqh150VUgy67WTTAdiBK2nBNuK6qs---QFPizWn5Muyq4ngzda6LxUaKZRQvPDvz_wpxV8L5tlMPjscRwgYl2xYIxlveVfAt_-Bd3FJofzFcKZF8WpUgQ5nyKWYc8LhMp9R8zdHc87RMG2EKTmWF28228VO2F_4Lbiiv9t0yCXAIUFwPl8wzlqtqRB_AHUnqbo</recordid><startdate>19980301</startdate><enddate>19980301</enddate><creator>GERDE, P</creator><creator>MUGGENBURG, B. A</creator><creator>SCOTT, G. G</creator><creator>LEWIS, J. L</creator><creator>PYON, K. H</creator><creator>DAHL, A. R</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>19980301</creationdate><title>Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure</title><author>GERDE, P ; MUGGENBURG, B. A ; SCOTT, G. G ; LEWIS, J. L ; PYON, K. H ; DAHL, A. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-757ba7de5d42d19c1b437264f8833a04d9e6b5fd98b343f978468aabf254bab63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Body Burden</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>Chemical agents</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Dogs</topic><topic>Female</topic><topic>Half-Life</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Polycyclic Compounds - metabolism</topic><topic>Polycyclic Compounds - toxicity</topic><topic>Pyrenes - administration &amp; dosage</topic><topic>Pyrenes - pharmacokinetics</topic><topic>Trachea - blood supply</topic><topic>Trachea - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GERDE, P</creatorcontrib><creatorcontrib>MUGGENBURG, B. A</creatorcontrib><creatorcontrib>SCOTT, G. G</creatorcontrib><creatorcontrib>LEWIS, J. L</creatorcontrib><creatorcontrib>PYON, K. H</creatorcontrib><creatorcontrib>DAHL, A. R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GERDE, P</au><au>MUGGENBURG, B. A</au><au>SCOTT, G. G</au><au>LEWIS, J. L</au><au>PYON, K. H</au><au>DAHL, A. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>1998-03-01</date><risdate>1998</risdate><volume>19</volume><issue>3</issue><spage>493</spage><epage>500</epage><pages>493-500</pages><issn>0143-3334</issn><issn>1460-2180</issn><eissn>1460-2180</eissn><coden>CRNGDP</coden><abstract>While inhaled polycyclic aromatic hydrocarbons have long been suspected to induce lung cancer in humans, their dosimetry has not been fully elucidated. A key question is whether the critical exposure occurs during absorption in the lungs, or if toxicants in the systemic circulation contribute significantly to lung cancer risk. In particular, data are needed to determine how the physical properties of inhalants affect local dosimetry in the respiratory tract. Pyrene, a tobacco smoke component, was selected for study because it has physical properties between those of highly lipophilic benzo[a]pyrene and water-soluble nitrosamines. Aliquots of 5 ng of pyrene dissolved in a phospholipid/ saline suspension were instilled as a single-spray bolus in the posterior trachea of the dog just anterior to the carina. For 3 h after instillation, blood was repeatedly sampled from the azygous vein, which drains the mucosa around the point of instillation, and from both sides of the systemic circulation. At 3 h post-instillation, tissue samples were taken. Autoradiography was used to determine the depth distribution of pyrene in the tracheal mucosa. The concentration of pyrene-equivalent radioactivity in the azygous vein peaked 9 min after the instillation. At approximately 30 min after instillation, a rapid early clearance phase shifted into a distinctly slower second clearance phase. Rates of rapid clearance were, however, sufficiently slow to indicate diffusion-limited absorption of pyrene in the trachea. This finding was corroborated by high concentrations of pyrene in the epithelium as determined by autoradiography. High epithelial concentration of pyrene combined with a slow penetration into the circulating blood allowed substantial first-pass metabolic conversion of pyrene in the tracheal mucosa. A total of 13% of the instilled pyrene was retained in the tracheal mucosa 3.2 h after instillation; of this, 29% was parent compound, 52% was organic-extractable metabolites, 14% was water-soluble metabolites and 6% (approximately 1% of the instilled amount) was covalently bound to tracheal tissues. Results support the inference that lipophilic protoxicants, because of slow, diffusion-limited absorption, are more likely than water-soluble protoxicants to be bioactivated in the lining epithelium and, in turn, induce first-pass toxicity at the site of entry. In addition, limitations were identified in the use of systemically distributed biomarkers of PAHs, such as urinary hydroxypyrene levels, as indicators of the biologically effective dose in airway target cells.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>9525285</pmid><doi>10.1093/carcin/19.3.493</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0143-3334
ispartof Carcinogenesis (New York), 1998-03, Vol.19 (3), p.493-500
issn 0143-3334
1460-2180
1460-2180
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_435352
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Biological and medical sciences
Biomarkers
Body Burden
Carcinogenesis, carcinogens and anticarcinogens
Chemical agents
Chromatography, High Pressure Liquid
Dogs
Female
Half-Life
Male
Medical sciences
Polycyclic Compounds - metabolism
Polycyclic Compounds - toxicity
Pyrenes - administration & dosage
Pyrenes - pharmacokinetics
Trachea - blood supply
Trachea - metabolism
Tumors
title Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A48%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20metabolism%20in%20lung%20airways%20increases%20the%20uncertainty%20of%20pyrene%20as%20a%20biomarker%20of%20polycyclic%20aromatic%20hydrocarbon%20exposure&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=GERDE,%20P&rft.date=1998-03-01&rft.volume=19&rft.issue=3&rft.spage=493&rft.epage=500&rft.pages=493-500&rft.issn=0143-3334&rft.eissn=1460-2180&rft.coden=CRNGDP&rft_id=info:doi/10.1093/carcin/19.3.493&rft_dat=%3Cproquest_swepu%3E36612551%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219335265&rft_id=info:pmid/9525285&rfr_iscdi=true